Acute Hepatocellular Injury Associated With Azithromycin

J Pharm Pract. 2021 Jun;34(3):493-496. doi: 10.1177/0897190019894428. Epub 2020 Jan 13.

Abstract

Purpose: A report of acute azithromycin-induced hepatocellular injury is described.

Summary: An 83-year-old male was admitted with possible community-acquired pneumonia and received azithromycin and ceftriaxone. After 2 doses of azithromycin, the patient's aspartate aminotransferase and alanine aminotransferase were greater than 3 times the upper limit of normal and continued to rise with subsequent doses. A diagnostic abdominal ultrasound revealed hepatomegaly. Total bilirubin remained within normal limits during the course. Rosuvastatin and fenofibrate were held on admission and were not resumed in the setting of elevated liver enzymes. Rivaroxaban was held in the setting of worsening renal function. Hepatitis serologies were negative. Liver enzymes, international normalized ratio (INR), and activated partial thromboplastin time (aPTT) continued to climb until hospital day 5 when azithromycin was discontinued in response. Liver enzymes, INR, aPTT, and lactate dehydrogenase all decreased from hospital days 6 through 8.

Conclusion: A potentially serious liver injury occurred with the initiation of azithromycin and began to resolve quickly after its discontinuation. While cholestatic injury with azithromycin is well described, this is only the third reported case of direct hepatocellular injury.

Keywords: azithromycin; hepatocellular liver injury.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Azithromycin / adverse effects
  • Carcinoma, Hepatocellular*
  • Chemical and Drug Induced Liver Injury* / diagnosis
  • Chemical and Drug Induced Liver Injury* / etiology
  • Humans
  • International Normalized Ratio
  • Liver Neoplasms*
  • Male

Substances

  • Azithromycin